|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
1
|
|
pubmed:dateCreated |
1995-6-9
|
|
pubmed:abstractText |
Twenty-two patients with severe atopic eczema were included in a therapy study with UV-A1 (wavelengths > 340 nm) treatment. The patients were divided into two dose groups, each consisting of 11 patients. One group received 10 J/cm2 and the other 50 J/cm2 five times a week for 3 consecutive weeks. No topical or systemical steroids or antihistamines were allowed. Using the SCORAD index as a measure of disease activity before onset of therapy and after 10 and 15 treatments, we observed a significant improvement in both dose groups after 15 treatments (10 J/cm2: p < 0.05, 50 J/cm2: p < 0.005). After 10 treatments only the improvement in the 50 J/cm2 group was significant (p < 0.005); the difference between the two dose groups was significant (p < 0.05). The clinical efficacy of treatment was reflected neither by a decrease of serum IgE nor by a decrease of elevated serum levels of soluble adhesion molecules sICAM-1 and sELAM-1 in the two dose groups. In contrast, a marked but not significant decrease of serum ECP could be observed in the 50 J/cm2 group only. We conclude from these and other published data that although 10 J/cm2 UV-A1 has a limited effect on patients with severe atopic eczema, higher doses are of higher efficiency in the treatment of this condition.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Blood Proteins,
http://linkedlifedata.com/resource/pubmed/chemical/Cell Adhesion Molecules,
http://linkedlifedata.com/resource/pubmed/chemical/E-Selectin,
http://linkedlifedata.com/resource/pubmed/chemical/Eosinophil Granule Proteins,
http://linkedlifedata.com/resource/pubmed/chemical/Immunoglobulin E,
http://linkedlifedata.com/resource/pubmed/chemical/Inflammation Mediators,
http://linkedlifedata.com/resource/pubmed/chemical/Intercellular Adhesion Molecule-1,
http://linkedlifedata.com/resource/pubmed/chemical/Membrane Glycoproteins,
http://linkedlifedata.com/resource/pubmed/chemical/Receptors, Immunologic,
http://linkedlifedata.com/resource/pubmed/chemical/Ribonucleases
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jan
|
|
pubmed:issn |
0001-5555
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
75
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
43-5
|
|
pubmed:dateRevised |
2004-11-17
|
|
pubmed:meshHeading |
pubmed-meshheading:7538257-Adult,
pubmed-meshheading:7538257-Blood Proteins,
pubmed-meshheading:7538257-Cell Adhesion Molecules,
pubmed-meshheading:7538257-Dermatitis, Atopic,
pubmed-meshheading:7538257-E-Selectin,
pubmed-meshheading:7538257-Eosinophil Granule Proteins,
pubmed-meshheading:7538257-Female,
pubmed-meshheading:7538257-Humans,
pubmed-meshheading:7538257-Immunoglobulin E,
pubmed-meshheading:7538257-Inflammation Mediators,
pubmed-meshheading:7538257-Intercellular Adhesion Molecule-1,
pubmed-meshheading:7538257-Male,
pubmed-meshheading:7538257-Membrane Glycoproteins,
pubmed-meshheading:7538257-Middle Aged,
pubmed-meshheading:7538257-Radiotherapy Dosage,
pubmed-meshheading:7538257-Receptors, Immunologic,
pubmed-meshheading:7538257-Remission Induction,
pubmed-meshheading:7538257-Ribonucleases,
pubmed-meshheading:7538257-Solubility,
pubmed-meshheading:7538257-Ultraviolet Therapy
|
|
pubmed:year |
1995
|
|
pubmed:articleTitle |
Low dose versus medium dose UV-A1 treatment in severe atopic eczema.
|
|
pubmed:affiliation |
Department of Dermatology, University of Hamburg, Germany.
|
|
pubmed:publicationType |
Journal Article
|
